India’s pharma sector funding, investment, mergers, and acquisitions activity during April 20–26 highlights a week shaped by mega M&A deals, strategic investments, and capital allocation moves. From Sun Pharma’s global acquisition to AI-driven...
Gujarat Themis Biosyn Limited (GTBL) has announced a major step in its global expansion with the signing of an agreement to acquire a portfolio of anti-tuberculosis and anti-infective brands from Sanofi. The GTBL acquisition of Sanofi TB...
India and Brazil on Saturday signed a India-Brazil MoU to strengthen cooperation in regulating pharmaceutical and medical products, marking a key move to deepen health sector ties. The agreement was formalized at Hyderabad House between Central...
Supriya Lifescience Limited has received a major regulatory boost as the U.S. Food and Drug Administration issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification for its API manufacturing unit in...
India’s CDSCO prior intimation mechanism is now live, marking a shift in how drug makers begin early-stage manufacturing for research. The Central Drugs Standard Control Organisation has rolled out the system from April 21, 2026, replacing the...
In a major move to control rising healthcare costs, the Centre has asked states to Uniform Hospital Rates across public and private healthcare facilities. The push aims to reduce wide price differences for the same treatments, which have been...
Aurobindo Pharma has announced a major expansion through its biologics arm TheraNym Biologics, committing USD 150–175 million investment to build a new biologics drug substance facility as part of its growing partnership with Merck Sharp & Dohme...
India is set to overhaul how biosimilar drugs are approved, with regulators proposing a major shift that could cut costs, speed up access, and reshape the pharmaceutical landscape. According to a report, DGCI is working on new biosimilar...
India’s drug regulator has significantly reduced approval timelines and relaxed several rules, in a move aimed at speeding up pharma innovation and making it easier for pharmaceutical companies to operate.
In an interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Atul Suri, Senior Vice President & SBU Head, Alembic Pharmaceuticals Limited, discusses how Indian pharma companies strengthen compliance, transparency, and ethical market
.jpg)
.jpg)
, CDSCO.jpg)